General Dynamics (GD)
(Real Time Quote from BATS)
$269.95 USD
-1.68 (-0.62%)
Updated Jan 22, 2025 02:44 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Price, Consensus and EPS Surprise
GD 269.95 -1.68(-0.62%)
Will GD be a Portfolio Killer in January?
Zacks Investment Research is releasing its prediction for GD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GD
Lockheed Stock Before Q4 Earnings: Should You Buy Now or Wait for Results?
General Dynamics (GD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
GD: What are Zacks experts saying now?
Zacks Private Portfolio Services
General Dynamics Wins a $188M Deal to Aid Virginia Class Submarines
General Dynamics (GD) Exceeds Market Returns: Some Facts to Consider
RTX Clinches a $946M Contract to Support Patriot Missile Program
Other News for GD
Morgan Stanley Reaffirms Their Buy Rating on General Dynamics (GD)
5 Defense Stocks to Buy for Trump 2.0
General Dynamics price target raised to $360 from $354 at Citi
General Dynamics price target raised by $6 at Citi, here's why
High-Quality Dividend Growth Stocks Near 52-Week Lows: Merck Is Magnificent